Clinical Trials Directory

Trials / Completed

CompletedNCT04296825

Effect of Camel Milk With Probiotic on Type 2 Diabetes Mellitus

Effect of Camel Milk Containing Bifidobacterium Animalis A6 on Chinese People With Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
45 (actual)
Sponsor
China Agricultural University · Academic / Other
Sex
All
Age
35 Years – 68 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the effects of dietary supplement with Camel Milk containing Bifidobacterium animalis A6 on the plasma glucose and other related cytokines in patients with type 2 diabetes mellitus. 45 patients with type 2 diabetes mellitus were recruited, and a Double Blind Randomized Parallel Controlled Trial was performed. The fasting glycaemia, 2 hour postprandial glycaemia, insulin, uric acid and serum lipid (total cholesterol, total triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol ) were measured as Primary Outcome. The Fecal microbiome, fecal metabolites, gut hormones (amylin, ghrelin, glucagon-like peptide 1, pancreatic polypeptide), inflammation cytokines (TNF-α, IL-6, MCP-1), myokines (FGF-21, irisin, osteocrin/musclin, osteonectin) and adipokines (adiponectin, resistin, lipocalin-2, adipsin) and body composition analysis were also assessed.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTCamel milk containing Bifidobacterium animalis A6Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
DIETARY_SUPPLEMENTCamel milkTake the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
DIETARY_SUPPLEMENTBifidobacterium animalis A6Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
DIETARY_SUPPLEMENTCow milkTake the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.

Timeline

Start date
2018-06-01
Primary completion
2018-06-09
Completion
2018-07-09
First posted
2020-03-05
Last updated
2020-03-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04296825. Inclusion in this directory is not an endorsement.